U.S. patent application number 09/971039 was filed with the patent office on 2002-03-28 for process for producing sustained-release preparation.
Invention is credited to Iwasa, Susumu, Taira, Keiko, Takada, Shigeyuki.
Application Number | 20020037837 09/971039 |
Document ID | / |
Family ID | 16255875 |
Filed Date | 2002-03-28 |
United States Patent
Application |
20020037837 |
Kind Code |
A1 |
Takada, Shigeyuki ; et
al. |
March 28, 2002 |
Process for producing sustained-release preparation
Abstract
The present invention is to provide sustained-release
microcapsules which contains high amount of a drug, suppresses
initial release and shows stable release, and the production method
of which comprises adding a physiologically active substance to
biodegradable polymer in an organic solvent containing a fat and
oil (in particular, vitamin E) and dispersing and emulsifying the
mixture.
Inventors: |
Takada, Shigeyuki; (Hyogo,
JP) ; Taira, Keiko; (Osaka, JP) ; Iwasa,
Susumu; (Kyoto, JP) |
Correspondence
Address: |
FITZPATRICK CELLA HARPER & SCINTO
30 ROCKEFELLER PLAZA
NEW YORK
NY
10112
US
|
Family ID: |
16255875 |
Appl. No.: |
09/971039 |
Filed: |
October 5, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09971039 |
Oct 5, 2001 |
|
|
|
09838232 |
Apr 20, 2001 |
|
|
|
09838232 |
Apr 20, 2001 |
|
|
|
09112317 |
Jul 9, 1998 |
|
|
|
6287587 |
|
|
|
|
Current U.S.
Class: |
424/400 ;
514/1.1; 514/11.4; 514/253.01; 514/254.01; 514/255.01 |
Current CPC
Class: |
A61K 31/495 20130101;
A61K 9/1617 20130101; Y10S 514/962 20130101; Y10S 514/937 20130101;
Y10S 514/938 20130101; A61K 9/1647 20130101; Y10S 514/963
20130101 |
Class at
Publication: |
514/2 ;
514/253.01; 514/254.01; 514/255.01 |
International
Class: |
A61K 038/00; A61K
031/495; A61K 031/496 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 15, 1997 |
JP |
190300-1997 |
Claims
What is claimed is:
1. A process for producing a sustained-release microcapsule of a
water-soluble physiologically active substance, which comprises
forming a w/o type emulsion comprising a solution containing a
water-soluble physiologically active substance as an inner aqueous
phase and an uniform organic solvent solution containing a
biodegradable polymer and a fat and oil as an oil phase, and
removing the organic solvent.
2. A process according to claim 1, wherein the w/o type emulsion is
dispersed in an aqueous phase, and the organic solvent is removed
by in-water drying.
3. A process according to claim 1, wherein the inner aqueous phase
is a solution containing a water-soluble physiologically active
substance and a basic substance.
4. A process according to claim 1, wherein the water-soluble
physiologically active substance is a polypeptide the molecular
weight of which ranges from about 200 to about 80,000.
5. A process according to claim 1, wherein the water-soluble
physiologically active substance is an integrin antagonist.
6. A process according to claim 5, wherein the integrin antagonist
is a GPIIb/IIIa antagonist.
7. A process according to claim 6, wherein the GPIIb/IIIa
antagonist is a 2-piperazinone-1-acetic acid derivative represented
by the formula (I): 10wherein A.sup.1 and A.sup.2 are independently
a proton-accepting group or a group convertible into a
proton-accepting group, D is a spacer having a 2- to 6-atomic chain
optionally bonded through a hetero atom and/or a 5- or 6-membered
ring (provided that the 5- or 6-membered ring is counted as 2- or
3-atomic chain, depending on its bonding position), R.sup.1 is a
hydrogen atom or hydrocarbon group, R.sup.2 is a hydrogen atom or a
residual group formed by removing --CH(NH.sub.2)COOH from an
.alpha.-amino acid, or R.sup.1 and R.sup.2may be combined to form a
5- or 6-membered ring, P is a spacer having a 1- to 10-atomic chain
optionally bonded through a hetero atom and/or a 5- or 6-membered
ring (provided that the 5- or 6-membered ring is counted as 2- or
3-atomic chain, depending on its bonding position), Y is an
optionally esterified or amidated carboxyl group, and n is an
integer of 0-8; or a salt thereof.
8. A process according to claim 7, wherein the
2-piperazinone-1-acetic acid derivative (I) is
(S)-4-(4-guanidinobenzoylamino)acetyl-3-[3-(4-guan-
idinobenzoylamino)]propyl-2-oxopiperazine-1-acetic acid or a salt
thereof.
9. A process according to claim 7, wherein the
2-piperazinone-1-acetic acid derivative (I) is
(S)-4-(4-guanidinobenzoylamino)acetyl-3-[3-(4-guan-
idinobenzoylamino)]propyl-2-oxopiperazine-1-acetic acid
hydrochloride.
10. A process according to claim 7, wherein the
2-piperazinone-1-acetic acid derivative (I) is
(S)-4-(4-guanidinobenzoylamino)acetyl-3-[3-(4-guan-
idinobenzoylamino)]propyl-2-oxopiperazine-1-acetic acid
dihydrochloride.
11. A process according to claim 1, wherein the biodegradable
polymer is an aliphatic polyester.
12. A process according to claim 11, wherein the aliphatic
polyester is a lactic acid/glycolic acid copolymer.
13. A process according to claim 1, wherein the fat and oil is an
oil soluble vitamin.
14. A process according to claim 13, wherein the oil soluble
vitamin is .alpha.-tocopherol.
15. A process according to claim 1, wherein the final concentration
of the fat and oil in a whole content of the sustained-release
microcapsule is about 3% to about 30% (w/w).
16. A process according to claim 1, wherein the W/O type emulsion
comprising a solution containing a water-soluble physiologically
active substance and a basic substance as an inner aqueous phase
and an uniform organic solvent solution containing a biodegradable
polymer and a fat and oil as an oil phase is dispersed in an
aqueous phase to form a W/O/W type emulsion, and the organic
solvent is removed by in-water drying.
17. A process according to claim 3 or 16, wherein the basic
substance is a basic amino acid.
18. A process according to claim 17, wherein the basic amino acid
is L-arginine.
19. A process according to claim 3 or 16, wherein the final
concentration of the basic substance in a whole content of the
sustained-release microcapsule is about 1% to about 8% (w/w).
20. A process for producing a sustained-release microcapsule, which
comprises removing an organic solvent from a S/O type dispersion
where a metal complex of a water-soluble physiologically active
peptide is dispersed in an uniform organic solvent solution
containing a biodegradable polymer and a fat and oil.
21. A process according to claim 20, wherein the S/O type
dispersion is dispersed in an aqueous phase to form a S/O/W type
emulsion, and the organic solvent is removed by in-water
drying.
22. A process according to claim 20, wherein the water-soluble
physiologically active peptide is human growth hormone.
23. A process according to claim 20, wherein the metal complex of
the water-soluble physiologically active peptide is a zinc complex
of human growth hormone.
24. A sustained-release microcapsule produced by the process
according to claim 1.
25. A sustained-release microcapsule produced by the process
according to claim 20.
26. Use of a fat and oil for the manufacture of a sustained-release
microcapsule of a water-soluble physiologically active substance,
said microcapsule being produced by forming a w/o type emulsion
comprising a solution containing the water-soluble physiologically
active substance as an inner aqueous phase and an organic solvent
solution containing a biodegradable polymer as an oil phase, and
removing the organic solvent.
27. Use of a fat and oil for the manufacture of a sustained-release
microcapsule of a metal complex of a water-soluble physiologically
active peptide.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to a sustained-release
microcapsule which suppresses initial release of an excess amount
of a physiologically active substance right after administration of
the microcapsule and releases stably a constant amount of the
physiologically active substance for a long time from right after
administration of the microcapsule, and a production method
thereof.
BACKGROUND OF THE INVENTION
[0002] On sustained-release microcapsules of various
physiologically active polypeptides or low molecular water-soluble
drugs, many reports have been made [Critical Reviews in Therapeutic
Drug Carrier Systems, 12, 1-9 (1995); JP-A H2(1990)2-503315;
EP-A-0586238; J. Pharm. Sci., 75, 750-755 (1986); JP-A
S57(1987)-118512]. Most of the microcapsules so far reported have
the following drawbacks:
[0003] (1) in the manufacturing process, the amount of the
water-soluble drug leaked to the outer aqueous phase is relatively
large to invite a relatively low entrapment ratio of the drug, (2)
the resulting microcapsules are generally porous and cause a
relatively large initial release, and (3) in the manufacturing
process, the physiologically active substance is denatured to
invite insufficient bioavailability. Thus, at the present stage,
sustained release of the drug over a desirable long period have not
yet been succeeded.
[0004] In JP-A S61(1986)-63613, improvement of sustained release of
microspheres was reported. That is, there is described that for the
purpose of preventing decrease of release rate of the active
ingredient a certain hour after administration of microspheres
whose base is polylactic acid, in an organic solvent of polylactic
acid to which the active ingredient is dispersed, an oil soluble
additive (medium chain fatty acid triglyceride, a lower fatty acid
triglyceride, etc.) which is soluble in said solvent and which is
biodegradable is uniformly dissolved. However, there is no
suggestion on application to the other bases nor on preparation of
microcapsules using a solution of the active ingredient.
[0005] In JP-A H8(1996)-151321 [EP-A-0709085], there is disclosed
microcapsules which contains an amorphous type water-soluble
physiologically active substance and polymer, and which are
produced from a S/O/W type emulsion. However, there is no
description on a process for producing microcapsules using a
solution of a drug as an inner aqueous phase nor on a method using
metal complex of a water-soluble physiologically active
peptide.
[0006] In EP 0765660, there is disclosed microcapsules which
contains an amorphous type 2-piperazinone-1-acetic acid derivative,
and in a production method thereof, a S/O/W type emulsion is
employed. However, there is no description on a process for
producing microcapsules using a solution of a drug as an inner
aqueous phase nor on a method using metal complex of a
water-soluble physiologically active peptide.
[0007] In general, in a process for producing microcapsules of a
water-soluble physiologically active substance, it is more
advantageous to employ a W/O type emulsion than a S/O type emulsion
where the drug is used as solid substances in view of equivalency
of drug content or operation, and it is desired to employ a W/O
type emulsion in an industrial manufacture with large scale.
OBJECT OF THE INVENTION
[0008] It is preferable for sustained-release preparations using
biodegradable polymers to suppress initial release of an excess
amount of a physiologically active substance, in particular release
of an excess amount of the same within one day after administration
thereof, and to releases stably a constant amount of the
physiologically active substance for a long time. The present
invention is to provide a simple and convenient process for
producing uniform sustained-release microcapsules which maintain
physiological activity of the physiologically active substance,
suppress initial release, and release stably a constant amount of
the physiologically active substance.
SUMMARY OF THE INVENTION
[0009] The present invention have intensively studied to solve the
above problems and, as a result, have found that in a process for
producing sustained-release microcapsules of a water-soluble
physiologically active substance, it is possible to produce very
useful sustained-release microcapsules which suppress initial
release of an excess amount of the physiologically active substance
right after administration and release stably a constant amount of
the physiologically active substance for a long time, by adding
about 3% to about 30% of a fat and oil to an organic solvent
solution of said biodegradable polymer and using the thus obtained
uniform solution as an oil phase. Further diligent studies based on
this finding have reached the accomplishment of the present
invention.
[0010] The present invention relates to
[0011] (1) A process for producing a sustained-release microcapsule
of a water-soluble physiologically active substance, which
comprises forming a w/o type emulsion comprising a solution
containing a water-soluble physiologically active substance as an
inner aqueous phase and an uniform organic solvent solution
containing (i) a biodegradable polymer and (ii) a "fat and oil" as
an oil phase, and removing the organic solvent;
[0012] (2) A process as described in the above (1), wherein the w/o
type emulsion is dispersed in an aqueous phase, and the organic
solvent is removed by in-water drying;
[0013] (3) A process as described in the above (1), wherein the
inner aqueous phase is a solution containing a water-soluble
physiologically active substance and a basic substance;
[0014] (4) A process as described in the above (1), wherein the
water-soluble physiologically active substance is a polypeptide the
molecular weight of which ranges from about 200 to about
80,000;
[0015] (5) A process as described in the above (1), wherein the
water-soluble physiologically active substance is an integrin
antagonist;
[0016] (6) A process as described in the above (5), wherein the
integrin antagonist is a GPIIb/IIIa antagonist;
[0017] (7) A process as described in the above (6), wherein the
GPIIb/IIIa antagonist is a 2-piperazinone-1-acetic acid derivative
represented by the formula (I): 1
[0018] wherein A.sup.1 and A.sup.2 are independently a
proton-accepting group or a group convertible into a
proton-accepting group, D is a spacer having a 2- to 6-atomic chain
optionally bonded through a hetero atom and/or a 5- or 6-membered
ring (provided that the 5- or 6-membered ring is counted as 2- or
3-atomic chain, depending on its bonding position), R.sup.1 is a
hydrogen atom or hydrocarbon group, R.sup.2 is a hydrogen atom or a
residual group formed by removing --CH(NH.sub.2)COOH from an
.alpha.-amino acid, or R.sup.1 and R.sup.2 may be combined to form
a 5- or 6-membered ring, P is a spacer having a 1- to 10-atomic
chain optionally bonded through a hetero atom and/or a 5- or
6-membered ring (provided that the 5- or 6-membered ring is counted
as 2- or 3-atomic chain, depending on its bonding position), Y is
an optionally esterified or amidated carboxyl group, and n is an
integer of 0-8; or a salt thereof;
[0019] (8) A process as described in the above (7), wherein the
2-piperazinone-1-acetic acid derivative (I) is
(S)-4-(4-guanidinobenzoyla-
mino)acetyl-3-[3-(4-guanidinobenzoylamino)]propyl-2-oxopiperazine-1-acetic
acid or a salt thereof;
[0020] (9) A process as described in the above (7), wherein the
2-piperazinone-1-acetic acid derivative (I) is
(S)-4-(4-guanidinobenzoyla-
mino)acetyl-3-[3-(4-guanidinobenzoylamino)]propyl-2-oxopiperazine-1-acetic
acid hydrochloride;
[0021] (10) A process as described in the above (7), wherein the
2-piperazinone-1-acetic acid derivative (I) is
(S)-4-(4-guanidinobenzoyla-
mino)acetyl-3-[3-(4-guanidinobenzoylamino)]propyl-2-oxopiperazine-1-acetic-
acid dihydrochloride;
[0022] (11) A process as described in the above (1), wherein the
biodegradable polymer is an aliphatic polyester;
[0023] (12) A process as described in the above (11), wherein the
aliphatic polyester is a lactic acid/glycolic acid copolymer;
[0024] (13) A process as described in the above (1), wherein the
fat and oil is an oil soluble vitamin;
[0025] (14) A process as described in the above (13), wherein the
oil soluble vitamin is .alpha.-tocopherol;
[0026] (15) A process as described in the above (1), wherein the
final concentration of the fat and oil in a whole content of the
sustained-release microcapsule is about 3% to about 30% (w/w);
[0027] (16) A process as described in the above (1), wherein the
W/O type emulsion comprising a solution containing a water-soluble
physiologically active substance and a basic substance as an inner
aqueous phase and an uniform organic solvent solution containing a
biodegradable polymer and a fat and oil as an oil phase is
dispersed in an aqueous phase to form a W/O/W type emulsion, and
the organic solvent is removed by in-water drying;
[0028] (17) A process as described in the above (3) or (16),
wherein the basic substance is a basic amino acid;
[0029] (18) A process as described in the above (17), wherein the
basic amino acid is L-arginine;
[0030] (19) A process as described in the above (3) or (16),
wherein the final concentration of the basic substance in a whole
content of the sustained-release microcapsule is about 1% to about
8% (w/w);
[0031] (20) A process for producing a sustained-release
microcapsule, which comprises removing an organic solvent from a
S/O type dispersion where a metal complex of a water-soluble
physiologically active peptide is dispersed in an uniform organic
solvent solution containing a biodegradable polymer and a fat and
oil;
[0032] (21) A process as described in the above (20), wherein the
S/O type dispersion is dispersed in an aqueous phase to form a
S/O/W type emulsion, and the organic solvent is removed by in-water
drying;
[0033] (22) A process as described in the above (20), wherein the
water-soluble physiologically active peptide is human growth
hormone;
[0034] (23) A process as described in the above (20), wherein the
metal complex of the water-soluble physiologically active peptide
is a zinc complex of human growth hormone;
[0035] (24) A sustained-release microcapsule produced by the
process according to the above (1);
[0036] (25) A sustained-release microcapsule produced by the
process according to the above (20);
[0037] (26) Use of a fat and oil for the manufacture of a
sustained-release microcapsule of a water-soluble physiologically
active substance, said microcapsule being produced by forming a w/o
type emulsion comprising a solution containing the water-soluble
physiologically active substance as an inner aqueous phase and an
organic solvent solution containing a biodegradable polymer as an
oil phase, and removing the organic solvent;
[0038] (27) Use of a fat and oil for the manufacture of a
sustained-release microcapsule of a metal complex of a
water-soluble physiologically active peptide; etc.
BRIEF DESCRIPTION OF THE DRAWING
[0039] FIG. 1 shows the time-course changes of the plasma level of
the drug after administration of the microcapsules used in Test
Example 1.
[0040] FIG. 2 shows the time-course changes of the plasma level of
the drug after administration of the microcapsules used in Test
Example 2.
DETAILED DESCRIPTION OF THE INVENTION
[0041] The abbreviations of amino acid, peptide, protecting group,
etc. in this specification are based on those established by
IUPAC-IUB Commission on Biochemical Nomenclature or those commonly
used in the relevant fields. When optical isomers of amino acids
are present, they are L-isomers unless otherwise specified. The
term "microcapsule" used in this specification includes
microspheres, microcapsules, microparticles, nanoparticles,
nanospheres, nanocapsules, etc. which contain a physiologically
active substance and a polymer.
[0042] The term "S/O/W type emulsion" and "W/O/W type emulsion"
used in this specification means a solid/oil/water (solid phase in
oil in water) type emulsion and a water/oil/water (water phase in
oil in water) type emulsion, respectively.
[0043] Examples of the water-soluble physiologically active
substances include any water-soluble drugs such as a
physiologically active polypeptide; a compound used as
anti-platelet aggregation agents (e.g. integrin antagonist),
anti-tumor agents, antibiotics, antipyretics, analgesics,
anti-inflammatory agents, antitussive expectorants, sedatives,
muscle relaxants, antiepileptic agents, antiulcer agents,
antidepressants, antiallergic agents, cardiotonics, antiarrhythmic
agents, vasodilators, hypotensive agents, diuretics, antidiabetic
agents, anticoagulants, hemostatics, antituberculous agents,
hormone preparations, narcotic antagonists, bone resorption
inhibitors, osteogenesis promoting agents, angiogenesis inhibitors,
etc.; etc.
[0044] Examples of said water-soluble physiologically active
substances include physiologically active substances whose
water-solubility at 25.degree. C. is not less than 0.1% (w/w),
preferably not less than 1% (w/w).
[0045] The physiologically active polypeptide as a component of the
present invention is exemplified by various peptides or proteins
that possess physiologically activity beneficial to mammals and
that can be used clinically. Said "physiologically active
polypeptide" has a molecular weight of, for example, about 200 to
about 200,000, calculated on a monomer basis, preferably about 200
to about 80,000. Preferred physiologically active polypeptides
include polymers classified in the biological field as proteins
having higher structure. Any kind of physiologically active
polypeptides can be used for the present invention, as long as the
object of the present invention is accomplished. Typical examples
include growth factors, cytokines, enzymes, hormones, etc. More
specifically, the following peptides and protein may be mentioned
as examples:
[0046] (1) Examples of the growth factors include nerve growth
factor (NGF-1, NGF-1, etc.), nerve trophic factor (NTF), epidermal
growth factor (EGF), platelet-derived growth factor (PDGF),
insulin-like growth factor (IGF-1, IGF-2, IGF-3, etc.), fibroblast
growth factor (aFGF, bFGF), osteogen growth factor (BMP-1, BMP-2,
BMP-3, BMP-4, etc.), atrial natriuretic factor (ANP), cartilage
induction factor, etc.
[0047] (2) Examples of the cytokines include interferon
(IFN-.alpha., IFN-.beta., IFN-.gamma., etc.), interleukin (IL-1 to
IL-11, etc.), cachectin, oncostatin, colony-stimulating factor
(G-CSF, M-CSF, GM-CSF, etc.), trombopoietin (TPO), erythropoietin
(EPO), etc.
[0048] (3) Examples of the enzymes include tissue plasminogen
activator (tPA), urokinase (UK), streptokinase, protein C,
metalloprotease, superoxide disumutase (SOD), Factor VIII and IX,
etc.
[0049] (4) Examples of the hormones include growth hormone (GH),
growth hormone-releasing factor (GRF), insulin, glucagon, gastrin,
prolactin, adrenocorticotrophic hormone (ACTH), thyroid-stimulating
hormone (TSH), follicle-stimulating hormone (FSH), luteinizing
hormone (LH), human chorionic gonadotropin (HCG), calcitonin,
etc.
[0050] Preferable examples of said physiologically active
polypeptide include hormones [e.g. growth hormone (human growth
hormone, etc.), insulin (human insulin, etc.), etc.], cytokines
(e.g. interferon, interleukin, etc.), etc.
[0051] The physiologically active polypeptide for the present
invention include polypeptides naturally derived and synthesized,
semi-synthesized or recombinant polypeptides produced by gene
recombination or peptide synthesis [e.g. recombinant human growth
hormone (hereinafter, referred to as rhGH)]. Such polypeptide may
have a sugar chain, and the structure of said sugar chain may be
different from that of natural polypeptide. Also, they include
muteins, derivatives, analogues, active fragments, etc. of the
physiologically active polypeptide or protein. Hereinafter, the
terms "physiologically active polypeptide", "growth hormones",
"insulins", "interferons" and "interleukins" are to be understood
to include respectively those having a sugar chain and their
muteins, derivatives, analogues and active fragments. When the
physiologically active polypeptide is muteins, derivatives or
analogues of an optional polypeptide, its mechanism of action may
be either agonistic or antagonistic.
[0052] The physiologically active polypeptide for the present
invention may be in a form of complex with a metal atom. Examples
of the metal complex of the polypeptide include a water insoluble
(or hardly soluble) polyvalent metal complex, metal salt, etc. of
the polypeptide. Any metal may be used for the metal complex
without limitation, as long as it is a metal that does not
adversely affect the living body. For example, a water-soluble
polyvalent metal (divalent, trivalent or tetravalent metal, e.g.
transition metal such as iron, copper, zinc, etc., IIIb group metal
such as aluminum, etc., Ivb group metal such as tin, etc.) is
preferably used.
[0053] Examples of the metal complex of the polypeptides include
physiologically active polypeptide metal salts obtained by
contacting a physiologically active polypeptide with a
water-soluble polyvalent metal salt (e.g. a salt of the above
polyvalent metal with an inorganic acid such as hydrochloric acid,
sulfuric acid, nitric acid, thiocyanic acid, etc. or a salt of the
above polyvalent metal with an organic acid such as aliphatic
carboxylic acid (e.g. aliphatic mono-, di- or tri-carboxylic acid,
preferably, aliphatic carboxylic acid having 2-9 carbon atoms,
etc.), aromatic acid (e.g. benzoic acid, salicylic acid, etc.),
etc.). Said physiologically active peptide metal salt can be
produced by mixing a physiologically active polypeptide with a
water-soluble polyvalent metal salt in a solution whose pH is
selected from the scope where solubility of both the reactants is
not extremely decreased.
[0054] Examples of ratio (mole ratio) of the physiologically active
polypeptide and the water-soluble polyvalent metal salt include 1:1
to 1:1000, preferably 1:1 to 1:100, more preferably 1:1 to 1:50. It
is preferable to employ concentration of both of the reactants
which is within the range of solubility of respective reactant and
which is over the range of solubility of the resulting complex. If
necessary, the solution to be employed may be adjusted to a weakly
acidic, neutral or weakly basic solution.
[0055] When the physiologically active polypeptide have an acidic
group (e.g. carboxyl group, sulfo group, etc.), it is advantageous
to use its water-insoluble complex (or complex which is hardly
soluble in water) with a polyvalent metal for the purpose of
improvement of entrapment into microcapsule and control of
release.
[0056] Examples of the anti-platelet aggregation agents include
integrin antagonists, in particular, GPIIb/IIIa antagonists.
Examples of the GPIIb/IIIa antagonists include snake venom peptide
(e.g. barbourin, or peptides having amino acid sequence:
Arg-Gly-Asp such as Arg-Gly-Asp-Ser, (Arg-Gly-Asp-Ser) tetramer,
Gly-Arg-Gly-Asp-Ser-Pro, cyclo-S,S-[AC-Cys(N
.alpha.-methyl)Arg-Gly-D-Asn-penicillamine]-NH.sub.2
(SK&F-106760: Pharm. Res., 11, 1358-1390, 1994), and a compound
having an activity similar to GPIIb/IIIa antagonistic activity such
as (S)-4-[(4-amidinobenzoyl)glycyl]-
-3-methoxy-carbonylmethyl-2-oxopiperazine-1-acetic acid,
4-(4-amidinobenzoylglycyl)-2-oxopiperazine-1,3-2-acetic acid
hydrochloride,
L-Tyr-N-(butylsulfonyl)-0-[4-(4-piperidinyl)butyl]monohydr-
ochloride (L-700462/MK-383: Circulation, 88, 1512-1517, 1993),
ethyl
3S-[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino-4-pentinoa-
te hydrochloride (SC-54684A: Circulation, 91, 403-410, 1995),
[1-[N-(P-amidinophenyl)-L-Tyr]-4-piperidinyl]acetic acid
(Ro-44-9883: Thromb. Haemostas., 70, 817-821, 1993),
cyclic[D-2-aminobutyryl-N-2-methy-
l-L-Arg-Gly-L-Asp-3-aminomethyl-benzoic acid]methane sulfonate
(DMP728: Circulation, 89, 3-12, 1994),
(3S-trans)-5-[[[4'-(aminoiminomethyl)-[1,1'-
-biphenyl]-4-yl]oxy]-methyl]-2-oxo-pyrrolidine-3-acetic acid
(Fradafiban; BIBU 52: Circulation, 96, 1130-1138, 1997) represented
by the formula: 2
[0057]
2(S)-[(p-toluenesulfonyl)amino]-3-[[[5,6,7,8-tetrahydro-4-oxo-5-[2--
(piperidin-4-yl)ethyl]-4H-pyrazoro[1,5-a][1,4]-diazepin-2-yl]carbonyl]amin-
o]propionic acid (L-738,167: The Journal of Pharmacology and
Experimental Therapeutics, 281, 677-689, 1997), Intrifiban
(Integrelin) (Circulation, 94, 2083-2089, 1996) represented by the
formula: 3
[0058] FK-633 (JP-A H5(1993)-148207) represented by the formula:
4
[0059] etc.
[0060] Further examples of the GPIIb/IIIa antagonists include
2-piperazinone-1-acetic acid derivative (I) represented by the
above formula (I) or a salt thereof, etc. Moreover, preferred
examples of the 2-piperazinone-1-acetic acid derivative include
those described in WO 96/33982 and, in particular, the
2-piperazinone-1-acetic acid derivative (I) represented by the
above formula (I) wherein A.sup.1 and A.sup.2 are independently (1)
an amidino group or a guanidino group, each of which may be
substituted with a C.sub.2-8 alkoxycarbonyloxy group or a C.sub.2-8
alkoxycarbonyl group, (2) an amino group optionally having an
oxadiazolyl group which may be substituted with a substituent
selected form an oxo group and an optionally halogenated C.sub.1-4
alkyl group, or (3) an oxadiazolyl group which may be substituted
with a substituent selected from an oxo group and an optionally
halogenated C.sub.1-4 alkyl group [preferably, (1) an amidino group
or a guanidino group, each of which may be substituted with a
methoxycarbonyloxy group or (2) an amino group optionally having a
substituent selected from a 5-oxo-1,2,4-oxadiazol-3-yl group and a
5-trifluoromethyl-1,2,4-oxadiazol-- 3-yl group]; D is a group of
the formula: 5
[0061] (wherein a is an integer of 0-2) [preferably, a phenylene
group]; R.sup.1 is a hydrogen atom; R.sup.2 is a hydrogen atom or a
C.sub.1-4 alkyl group optionally having a phenyl group which may be
substituted with a C.sub.1-4 alkoxy group [preferably, a hydrogen
atom or a p-methoxybenzyl group]; P is a group of the formula:
--Z--B-- (wherein Z is a chemical bond, --NH-- or --NH--CO-- and B
is a group of the formula: 6
[0062] or --(CH.sub.2).sub.c-- (wherein b is an integer of 0-1 and
c is an integer of 1-5)) [preferably, a group of the formula: 7
[0063] ]; Y is a group of the formula: --CO--R.sup.7 (wherein
R.sup.7 is (1) a hydroxy group, (2) a C.sub.1-8 alkoxy group or a
C.sub.2-12 alkenyloxy group, each of which may be substituted with
a substituent selected from a C.sub.1-4 alkoxy-carbonyl group or a
5-methyl-2-oxo-1,3-dioxolen-4-yl group, or (3) a group of the
formula: --OCH(R.sup.7a)OCOR.sup.8 (wherein R.sup.7a is a hydrogen
atom or a C.sub.1-6 alkyl group and R.sup.8 is a C.sub.1-6 alkyl
group or a C.sub.5-7 cycloalkyloxy group)) [preferably, a carboxyl
group]; and n is an integer of 1-4 [preferably, an integer of 2-3];
is preferable.
[0064] More preferred examples of the 2-piperazinone-1-acetic acid
derivative (I) include
(S)-4-(4-guanidinobenzoylamino)acetyl-3-[3-(4-guan-
idinobenzoylamino)]propyl-2-oxopiperazine-1-acetic acid,
(S)-4-(4-amidinobenzoyl-amino)acetyl-3-[3-(4-amidinobenzoyl-amino)]propyl-
-2-oxopiperazine-1-acetic acid, or their hydrochloride,
dihydrochloride, acetate, etc. Among others, hydrochloride of
(S)-4-(4-guanidinobenzoylami-
no)acetyl-3-[3-(4-guanidinobenzoylamino)]propyl-2-oxopiperazine-1-acetic
acid is preferable and, in particular,
(S)-4-(4-guanidinobenzoylamino)ace-
tyl-3-[3-(4-guanidinobenzoyl-amino)]propyl-2-oxopiperazine-1-acetic
acid hydrochloride or
(S)-4-(4-guanidinobenzoylamino)acetyl-3-[3-(4-guanidinob-
enzoylamino)]propyl-2-oxopiperazine-1-acetic acid dihydrochloride
is preferable. Said
(S)-4-(4-guanidinobenzoylamino)acetyl-3-[3-(4-guanidinob-
enzoylamino)]propyl-2-oxopiperazine-1-acetic acid dihydrochloride
can be prepared by adding concentrated hydrochloric acid to a
solution containing
(S)-4-(4-guanidinobenzoylamino)acetyl-3-[3-(4-guanidinobenzoyl-
amino)]propyl-2-oxopiperazine-1-acetic acid hydrochloride and
adjusting pH of the solution to about 1-2 (preferably about 1.5),
and the obtained
(S)-4-(4-guanidinobenzoylamino)acetyl-3-[3-(4-guanidinobenzoylamino)]prop-
yl-2-oxopiperazine-1-acetic acid dihydrochloride can be
crystallized with ethanol, etc.
[0065] Examples of the above-mentioned anti-tumor agents include
bleomycin, methotrexate, actinomycin D, mitomycin C, vinblastine
sulfate, vincristine sulfate, daunorbicin, adriamycin,
neocarzinostatin, cytosine arabinoside, fluorouracil,
tetrahydrofuryl-5-fluorouracil, krestin, picibanil, lentinan,
levamisole, bestatin, glycyrrhizin, polynucleic acids such as poly
IC, poly AU, poly ICLC, etc. [Immune Response (Yuichi YAMAMURA and
Seiji MORISAWA; 1977), page 143], etc.
[0066] Examples of the above-mentioned antibiotics include
gentamycin, dibekacin, kanendomycin, lividomycin, tobramycin,
amikacin, fradiomycin, sisomycin, tetracycline hydrochloride,
oxytetracycline hydrochloride, rolitetracycline, doxycycline
hydrochloride, ampicillin, piperacillin, ticarcillin, cefalotin,
cefaloridine, cefotiam, cefsulodin, cefmenoxime, cefmetazole,
cefazolin, cefotaxime, cefoperazone, ceftizoxime, moxolactam,
thienamycin, sulfazecin, azusleonam, etc.
[0067] Examples of the above-mentioned antipyretics, analgesics and
anti-inflammatory agents include salicylic acid, sulpyrine,
flufenamic acid, diclofenac, indomethecin, morphine, pethidine
hydrochloride, levorphanol tartarate, oxymorphone, etc.
[0068] Examples of the above-mentioned antitussive expectorants
include ephedrine hydrochloride, methylephedrine hydrochloride,
noscapine hydrochloride, codeine phosphate, dihydrocodeine
phosphate, alloclamide hydrochloride, chlorphezianol hydrochloride,
picoperidamine hydrochloride, cloperastine, protokylol
hydrochloride, isoproterenol hydrochloride, salbutamol sulfate,
terebutaline sulfate, etc.
[0069] Examples of the above-mentioned sedatives include
chlorpromazine, prochlorperazine, trifluoperazine, atropine
sulfate, methylscopolamine bromide, etc.
[0070] Examples of the above-mentioned muscle relaxants include
pridinol methanesulfonate, tubocurarine chloride, pancuronium
bromide, etc.
[0071] Examples of the above-mentioned antiepileptic agents include
phenytoin, ethosukimide, acetazolamide sodium, chlordiazepoxide,
etc.
[0072] Examples of the above-mentioned antiulcer agent include
metoclopramide, histidine hydrochloride, etc.
[0073] Examples of the above-mentioned antidepressants include
imipramine, clomipramine, noxiptilin, phenelzine sulfate, etc.
[0074] Examples of the above-mentioned antiallergic agents include
diphenhydramine hydrochloride, chlorpheniramine maleate,
tripelennamine hydrochloride, clemizole hydrochloride,
diphenylpyraline hydrochloride, methoxyphenamine hydrochloride,
etc.
[0075] Examples of the above-mentioned cardiotonics include
transbioxocamphor, theophyllol, aminophylline, etilefrine
hydrochloride, etc.
[0076] Examples of the above-mentioned antiarrhythmic agents
include propranolol, alprenolol, bufetolol, oxyprenolol, etc.
[0077] Examples of the above-mentioned vasodilators include
oxyfedrine hydrochloride, diltiazem, tolazoline hydrochloride,
hexobendine, bamethan sulfate, etc.
[0078] Examples of the above-mentioned hypotensive diuretics
include hexamethonium bromide, pentolinium, mecamylamine
hydrochloride, ecarazine hydrochloride, clonidine, etc.
[0079] Examples of the above-mentioned antidiabetic agents include
glymidine sodium, glipizide, phenformin hydrochloride, buformin
hydrochloride, metformin, etc.
[0080] Examples of the above-mentioned anticoagulants include
heparin sodium, sodium citrate, etc.
[0081] Examples of the above-mentioned hemostatics include
thromboplastin, thrombin, menadione sodium bisulfite,
acetomenaphthone, .epsilon.-aminocaproic acid, tranexamic acid,
carbazochrome sodium sulfate, adrenochrome monoaminoguanidine
methanesulfonate, etc.
[0082] Examples of the above-mentioned antituberculous agents
include isoniazid, ethambutol, para-aminosalicylic acid, etc.
[0083] Examples of the above-mentioned hormone preparations include
prednisolone, prednisolone sodium phosphate, dexamethasone sodium
sulfate, betamethasone sodium phosphate, hexoestrol phosphate,
hexoestrol acetate, methimazole, etc.
[0084] Examples of the above-mentioned narcotic antagonists include
levallorphan tartarate, nalorphine hydrochloride, naloxone
hydrochloride, etc.
[0085] Examples of the above-mentioned bone resorption inhibitors
include (sulfur-containing alkyl)aminomethylenebisphosphonic acid,
etc.
[0086] Examples of the above-mentioned osteogenesis promoting
agents include vitamin K2 or parathyroid hormone, or a compound of
the formula (II): 8
[0087] wherein ring A is an optionally substituted benzene ring, R
is a hydrogen atom or an optionally substituted hydrocarbon group,
B is an optionally esterified or amidated carboxyl group, X is
--CH(OH)-- or --CO--, k is 0 or 1, and k' is 0, 1 or 2, or a salt
thereof, etc. (JP-A H3(1991)-232880, JP-A H4(1992)-364179).
[0088] Examples of the above-mentioned angiogenesis inhibitors
include angiostatic steroid [Science, 221, 719 (1983)], fumagillin
[EP-A-325199], fumagillol derivatives [EP-A-357061, EP-A-359036,
EP-A-386667, EP-A-415294], etc.
[0089] The physiologically active substance may be distinct entity
or in the form of any possible pharmaceutical salts thereof (e.g. a
salt with an inorganic acid such as hydrochloric acid, sulfuric
acid, nitric acid, etc. or a salt with an organic salt such as
carbonic acid, succinic acid, etc., when the physiologically active
substance has a basic group such as an amino group, etc.; a salt
with an inorganic base such as alkaline metals (e.g. sodium,
potassium, etc.), a salt with a basic organic compound such as
organic amines (e.g. triethylamine, etc.), basic amino acids (e.g.
arginine, etc.), etc., when the physiologically active substance
has an acidic group such as carboxyl group, etc.). When the
physiologically active substance is distinct entity and
water-insoluble, it can be converted into a water-soluble salt
thereof.
[0090] In the sustained-release microcapsule, the amount of the
physiologically active substance to be used varies with factors
related to the particular kind of the physiologically active
substance, desired pharmacological activity, duration time, etc.
The amount of the physiologically active substance in the
microcapsule ranges preferably from about 0.01% to about 50% (W/W),
more preferably from about 0.1% to about 30% (W/W).
[0091] Examples of the biodegradable polymer to be used in the
present invention include poly fatty acid esters (e.g. polylactic
acid, polyglycolic acid, polycitric acid, polymalic acid,
polylactic acid caprolactone, etc.), poly-.alpha.-cyanoacrylic acid
esters, poly-.beta.-hydroxybutyric acids, polyalkylene oxalates
(e.g. polytrimethyleneoxalate, polytetramethyleneoxalate, etc.),
polyortho-esters, polyortho-carbonates, other polycarbonates (e.g.
polyethylene-carbonate, polyethylene-propylene-carbonate, etc.),
polyamino acids (e.g. poly-.gamma.-benzyl-L-glutamic acid,
poly-L-alanine, poly-.gamma.-methyl-L-glutamic acid, etc.),
hyaluronic acid esters, etc.
[0092] These polymers may optionally be used singly or as a
copolymer of two or more of them or as a simple mixture of them or
in the form of their salts.
[0093] The biodegradablity of these biodegradable polymer is
defined as the percentage (w/w %) of water-soluble low-molecular
weight fragments degraded from the polymer relative to the polymer
when the polymer is used as injectable preparations, and in
general, it should be not less than 10% in three months after
subcutaneous or intramuscular administration, preferably, not less
than 80% in one year after subcutaneous or intramuscular
administration.
[0094] Said biodegradable polymer is preferably aliphatic
polyester. Examples of said biodegradable polymer include an
aliphatic polyester (a poly fatty acid ester), more preferably,
polymers or copolymers of hydroxycarboxylic, or mixtures
thereof.
[0095] The hydroxycarboxylic acids are not specifically limited,
but preferably hydroxycarboxylic acids of the formula: 9
[0096] wherein R is a hydrogen atom or an alkyl group.
[0097] In the above formula, examples of the alkyl group
represented by R includes a straight or branched alkyl group having
1 to 8 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, butyl,
isobutyl, tertiary butyl, pentyl, hexyl, heptyl, octyl, etc.).
Among others, a straight or branched alkyl group having 1 to 3
carbon atoms is more preferable.
[0098] Preferred examples of the above hydroxycarboxylic acid
include glycolic acid, lactic acid, hydroxybutyric acid (e.g.
2-hydroxybutyric acid), 2'-hydroxyvaleric acid,
2-hydroxy-3-methylbutyric acid, 2-hydroxycaproic acid,
2-hydroxyisocaproic acid, 2-hydroxycaprylic acid, etc. Among
others, glycolic acid, lactic acid, 2-hydroxybutyric acid,
2-hydroxy-3-methylbutyric acid, 2-hydroxycaproic acid, etc. are
preferable. In particular, glycolic acid, lactic acid,
2-hydroxybutyric acid, etc. are more preferable. Where these
hydroxycarboxylic acids exist as D-isomers, L-isomers and D,
L-isomers (racemic mixtures of D-isomer and L-isomer), any one of
them may be used. Preferably, D,L-isomers are used.
[0099] The copolymers may be any of random, block and graft
copolymers. Preferred examples of the glycolic acid copolymer
include the copolymer that degrades in living body relatively
rapidly and has a release period of not more than one month when
used alone. In particular, lactic acid/glycolic acid homopolymer or
copolymer (hereinafter, referred to as "lactic acid/glycolic acid
polymer" or abbreviated to "PLGA", both of which always include
copolymers and homopolymers of the respective acids) or
hydroxybutyric acid/glycolic acid homopolymer or copolymer
(hereinafter, referred to as "hydroxybutyric acid/glycolic acid
copolymer", which always include copolymers and homopolymers of the
respective acids) is preferable.
[0100] The biodegradable polymer to be used in the present
invention can be synthesized by general synthetic methods (e.g.
those described in JP-A S61(1986)-28521), without any problem.
[0101] In general, the weight-average molecular weight of the
biodegradable polymer to be used in the present invention ranges
preferably from about 2,000 to about 800,000, more preferably from
about 5,000 to about 200,000. When lactic acid/glycolic acid
copolymer is used as the above-mentioned polymer, the molar ratio
of lactic acid/glycolic acid ranges preferably from 100/0 to about
25/75, more preferably from about 100/0 to about 50/50. The
weight-average molecular weight of lactic acid/glycolic acid
copolymer ranges preferably about 5,000 to about 30,000, more
preferably from about 5,000 to about 20,000.
[0102] When hydroxybutyric acid/glycolic acid copolymer (e.g.
2-hydroxybutyric acid/glycolic acid copolymer) is used as the
above-mentioned polymer, the molar ratio of hydroxybutyric
acid/glycolic acid ranges preferably from about 100/0 to about
25/75, more preferably from about 100/0 to about 50/50. In
particular, the molar ratio of 2-hydroxybutyric acid/glycolic acid
ranges from preferably about 60/40 to about 30/70. The
weight-average molecular weight of hydroxybutyric acid/glycolic
acid copolymer ranges preferably from about 5,000 to about 25,000,
more preferably from about 5,000 to about 20,000.
[0103] When butyric acid/glycolic acid copolymer is used as the
above-mentioned polymer, the molar ratio of butyric acid/glycolic
acid ranges preferably from about 100/0 to about 25/75.
[0104] When a mixture of polylactic acid (A) and glycolic
acid/2-hydroxybutyric acid copolymer(B) is used as the
above-mentioned polymer, the mixing ratio of (A) /(B) ranges from
about 10/90 to about 90/10 (by weight), preferably from about 25/75
to about 75/25 (by weight). The weight-average molecular weight of
polylactic acid ranges preferably from about 5,000 to about 30,000,
more preferably from about 6,000 to about 20,000.
[0105] In the present specification, the weight-average molecular
weight means a molecular weight in terms of the molecular weight of
polystyrene determined by gel permeation chromatography (GPC) using
polystyrene as the standard material. More specifically, the
weight-average molecular weight is based on polystyrene, obtained
by gel permeation chromatography (GPC) with 9 polymers of
polystyrene as reference substances with weight-average molecular
weights of 120,000, 52,000, 22,000, 9,200, 5,050, 2,950, 1,055, 580
and 162, respectively. The determination was carried out using GPC
column KF804LX2 (manufactured by Showa Denko K. K., Japan) and RI
monitor L-3300 (Hitachi, Japan) and using chloroform as the mobile
phase.
[0106] The polydispersity of said polymer is defined as the value
of weight average molecular weight/number average molecular weight,
which ranges, in general, from 1 to 3.5, preferably from 1.5 to
2.5. The amount of the biodegradable polymer to be used depends
upon, for example, the degree of the pharmacological activity of
the physiologically active substance, release rate of said
substance, release period of said substance, etc. For example, the
polymer is used is used as the microcapsule base in an amount of
about 0.2 to about 10000 times (by weight), preferably about 1 to
about 1000 times (by weight) relative to the weight of the
physiologically active substance. The concentration of the
biodegradable polymer in an oil phase ranges preferably from about
0.5 to about 90% (W/W), more preferably about 2 to about 60%
(W/W).
[0107] Examples of the "fat and oil" to be added to an organic
solvent of the above biodegradable polymer include any fat and oil
which is dissolved in said organic solvent without causing phase
separation and which is degradable and absorbable in living body,
and preferably excluding a fatty acid, a salt thereof, a glycerin
fatty acid ester and a propylene glycol fatty acid ester. Examples
of the fat and oil include an oil soluble vitamin (vitamin A,
vitamin D, vitamin E, vitamin K, etc.), medium chain fatty acid
triglyceride (triglycerol of fatty acid having 8-12 carbon atoms
such as miglyol, etc.), cholesterol, phospholipids, etc. Preferable
examples of the fat and oil include an oil soluble vitamin (vitamin
A, vitamin D, vitamin E, vitamin K, etc.), cholesterol,
phospholipids, etc., more preferably an oil soluble vitamin such as
.alpha.-tocopherol (vitamin E), .alpha.-tocopherol acetate (vitamin
E acetate), etc.
[0108] A final concentration of the fat and oil to be added to an
organic solvent of the above biodegradable polymer ranges from
about 1% to about 50% (W/W), more preferably from about 3% to about
30% (W/W) relative to a whole content of the sustained-release
microcapsules.
[0109] In the present invention, when the sustained-release
microcapsules are produced by a W/O technique or a W/O/W technique,
a basic substance may be further added to an aqueous phase
containing the physiologically active substance. In particular,
when the physiologically active substance is an acidic drug or an
acidic salt of the drug (hydrochloride, etc.) (for example, pH of
the aqueous phase is 6 or less), it is preferable to add the basic
substance. Examples of the basic substance include a basic amino
acid such as L-histidine, L-arginine, L-lysine, etc.,
N-methylglucamine, etc.
[0110] The final concentration of the basic substance to be added
to the solution of the physiologically active substance ranges from
about 0.1% to about 20% (W/W) relative to a whole content of the
sustained-release microcapsule, more preferably about 1% to about
8% (W/W). In the present invention, it is preferable to allow an
osmotic pressure adjustor to be contained in the outer aqueous
phase when removal of the organic solvent is carried out by
in-water drying.
[0111] Any osmotic pressure adjustor can be employed so long as it
produces osmotic pressure in an aqueous solution thereof.
[0112] Examples of the osmotic pressure adjustor include
water-soluble polyhydric alcohols, water-soluble monovalent
alcohols, water-soluble inorganic materials (e.g. inorganic salts),
water-soluble monosaccharides, disaccharides, oligosaccharides
polysaccharides or its derivative, water-soluble organic acids or a
salt thereof, water-soluble amino acid, water-soluble peptide,
protein or its derivative, etc. Among others, water-soluble
polyhydric alcohols, water-soluble inorganic materials,
water-soluble monosaccharides, disaccharides, oligosaccharides
polysaccharides or its derivative, water-soluble organic acid or a
salt thereof, etc. are preferable. In particular, salts,
water-soluble polyhydric alcohols and water-soluble inorganic
materials are preferable.
[0113] Examples of the above water-soluble inorganic salts include
halogenated alkali metals such as potassium chloride, sodium
chloride, potassium bromide, sodium bromide, potassium iodide,
sodium iodide, etc., halogenated alkaline earth metals such as
calcium chloride, magnesium chloride, etc., alkali metal sulfates
such as sodium sulfate, potassium sulfate, etc., alkaline earth
metal sulfates such as magnesium sulfate, calcium sulfate, etc.,
alkali metal phosphates such as potassium dihydrogenphosphate,
dipotassium hydrogenphosphate, potassium phosphate, sodium
dihydrogenphosphate, disodium hydrogenphosphate, sodium phosphate,
etc., etc. Among others, sodium chloride is preferable.
[0114] Examples of the above water-soluble polyhydric alcohol
include dihyrdic alcohols such as glycerin, etc., pentahydric
alcohols such as arabitol, xylitol, adonitol, etc., hexahydric
alcohols such as mannitol, sorbitol, etc., etc. Among others,
hexahydric alcohols are preferable. Examples of the above
water-soluble monovalent alcohol include methanol, ethanol,
isopropyl alcohol, etc. Among others, ethanol is preferable.
Examples of the above water-soluble monosaccharides include
pentoses such as arabinose, xylose, ribose, 2-deoxyribose, etc.,
hexoses such as glucose, fructose, galactose, mannose, sorbose,
rhamnose, fucose, etc. Among others, hexoses are preferable.
[0115] Examples of the above water-soluble disaccharides include
maltose, cellobiose, .alpha.-trehalose, lactose, sucrose, etc.
Among others, lactose and sucrose are preferable.
[0116] Examples of the above water-soluble oligosaccharides include
trisaccharides such as maltotriose, raffinose, etc.,
tetrasaccharides such as stachyose, etc., etc. Among others,
trisaccharides are preferable.
[0117] Examples of the above water-soluble polysaccharides include
glucans such as cellulose, starch, glycogen, etc., galacturonans
such as pectic acid, etc., mannuronans such as alginic acid, etc.,
fructans such as inulin, levan, etc., N-acetylglycosamine polymers,
such as chitin, etc., xylans such as xylan of rice straw, etc.,
diheteroglucans such as mannan, glucomannan, galactomannan,
hyaluronic acid, chondroitin sulfate, heparin, etc., etc. Among
others, glucans, diheteroglucans, etc. are preferable.
[0118] Examples of the derivatives of the above water-soluble
monosaccharides, disaccharides, oligosaccharides and
polysaccharides include glucosamine, galactosamine, glucuronic
acid, galacturonic acid, etc. Examples of the above water-soluble
organic acid or a salt thereof include citric acid, tartaric acid,
malic acid, their alkali metal salt (e.g. sodium salt, potassium
salt, etc.), etc. Examples of the above water-soluble amino acid
include neutral amino acid such as glycine, alanine, valine,
leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine,
threonine, proline, hydroxyproline, cyctein, methionine, etc.,
acidic amino acid such as aspartic acid, glutamic acid, etc., basic
amino acid such as lysine, arginine, histidine, etc., etc. Salts of
these water-soluble amino acid with acids (e.g. hydrochloric acid,
sulfuric acid, phosphoric acid, etc.) or alkalis (e.g. alkali metal
such as sodium, potassium, etc., etc.) are also used optionally.
Examples of the water-soluble peptide, protein or their derivative
include casein, globulin, prolamin, albumin, gelatin, protamine,
histone, etc.
[0119] These osmotic pressure adjustor may be used alone or as a
mixture of two or more of them. When the osmotic pressure adjustor
is a non-ionic material, the concentration of the osmotic pressure
adjustor in the outer aqueous phase ranges from about 0.001 to
about 60% (W/W), preferably from about 0.01 to about 40% (W/W),
more preferably from about 0.05 to about 30% (W/W). When the
osmotic pressure adjustor is an ionic material, it is used in a
concentration calculated by dividing the above-mentioned
concentration by the total ionic valency. The concentration of the
osmotic pressure adjustor to be added is not necessarily below
their solubility, and a part of it may be left in the state of
dispersion in the solvent.
[0120] Each step of the production method of the present invention
is carried out, for example, as follows:
[0121] In the process for producing the microcapsule where a
solution of the water-soluble physiologically active substance is
used as an aqueous phase, the water-soluble physiologically active
substance (hereinafter, briefly referred to as the drug) is
dissolved in water, and if necessary, basic substances such as
above-mentioned basic amino acid, etc. and additionally
pharmaceutical carriers such as e.g. gelatin, agar,
polyvinylalcohol, etc. are added to the solution to prepare an
aqueous phase (an inner aqueous phase).
[0122] The concentration of the drug in the inner aqueous phase
ranges preferably from about 0.1 to about 150% (W/V), more
preferably about 20 to about 130% (W/V), and in particular, about
60 to about 120% (W/V).
[0123] As pH regulators to maintain the stability and solubility of
the drug, for example, carbonic acid, acetic acid, oxalic acid,
citric acid, phosphoric acid, hydrochloric acid, sodium hydroxide,
arginine, lysine and their salts, etc. can be added to said aqueous
phase. Further, as stabilizers of the drug, there can be added, for
example, albumin, gelatin, citric acid, sodium
ethylenediaminetetraacetate, dextrin, sodium hydrogensulfite,
polyols such as polyethyleneglycol, etc., etc., and as
preservatives there can be added, for example, conventional
para-oxybenzoic acid esters (e.g. methylparaben, propylparaben,
etc.), benzylalcohol, chlorobutanol, thimerosal, etc.
[0124] The thus obtained aqueous phase is added to a uniform
organic solvent solution (an oil phase) containing the
biodegradable polymer (hereinafter, briefly referred to as the
polymer) and a fat and oil, followed by emulsification to prepare a
W/O type emulsion. The emulsification can be carried out by
conventional dispersion techniques such as intermittent shaking,
mixing by means of a mixer (e.g. propeller agitator, turbine
agitator, etc.), colloid mill operation, mechanical homogenization,
ultrasonication, etc.
[0125] The above polymer solution (oil phase) can be prepared by
dissolving the polymer in an organic solvent which does not
substantially mix with water. The water-solubility of said organic
solvent is preferably not more than 3% (W/W) at standard
temperature (20.degree. C.), and the boiling point of said organic
solvent is preferably not more than 120.degree. C. Examples of the
organic solvent include halogenated hydrocarbons (e.g.
dichloromethane, chloroform, chloroethane, trichloroethane, carbon
tetrachloride, etc.), alkyl ethers having 3 or more carbon atoms
(e.g. isopropylether, etc.), fatty acid alkyl (having 4 or more
carbon atoms) esters (e.g. butyl acetate, etc.), aromatic
hydrocarbons (e.g. benzene, toluene, xylene, etc.), etc. These
solvents can be used alone or in combination thereof. As the
organic solvent, halogenated hydrocarbons (e.g. dichloromethane,
chloroform, chloroethane, trichloroethane, carbon tetrachloride,
etc.) are more preferable, and in particular, dichloromethane is
preferable.
[0126] Removal of the organic solvent from the thus produced W/O
type emulsion can be carried out by a conventional method. Examples
of the removal method of the organic solvent include spray drying,
in-water drying, etc., preferably in-water drying.
[0127] In the spray drying technique, the produced W/O type
emulsion is ejected in a mist form through a nozzle, etc. into the
drying chamber of a spray drier to evaporate the solvent from the
finely-divided liquid droplets in a brief time. Examples of the
nozzle include a two-fluid nozzle, pressure nozzle, rotary disk
nozzle, etc.
[0128] In the in-water drying, the produced W/O type emulsion is
added to an aqueous phase (an outer aqueous phase) to form a W/O/W
type emulsion, followed by removing the organic solvent in the oil
phase. The volume of the outer aqueous phase is generally selected
from the range of about 1 to about 10,000 times the volume of the
oil phase, more preferably about 2 to about 5,000 times, and in
particular, about 5 to about 2,000 times.
[0129] Any emulsifier may be added to the above outer aqueous
phase, as long as it can contribute to the formation of a stable
W/O/W type emulsion. Examples of the emulsifiers include anionic
surfactants (sodium oleate, sodium stearate, sodium lauryl sulfate,
etc.), non-ionic surfactants (polyoxy-ethylene-sorbitan fatty acid
esters [Tween 80, Tween 60; Atlas Powder], polyoxyethylene-castor
oil derivatives [HCO-60, HCO-50; Nikko Chemicals], etc.),
polyvinylpyrrolidone, polyvinylalcohol, carboxymethylcellulose,
lecithin, gelatin, hyaluronic acid, etc., preferably
polyvinylalcohol. These emulsifiers can be used independently or in
combination. The concentration may be selected from about 0.001 to
about 20% (W/W), more preferably about 0.01 to about 10% (W/W), and
in particular, from about 0.05 to about 5% (W/W).
[0130] The above-mentioned osmotic pressure adjustor may be added
to an outer aqueous phase. In the production method of the present
invention, it is preferable to adjust viscosity of the W/O type
emulsion in the range of from about 150 centipoise (cp) to about
10,000 cp when the W/O/W type emulsion is formed.
[0131] Examples of the methods to adjust viscosity include (1) a
method for adjusting the concentration of the biodegradable polymer
in oil phase, (2) a method for adjusting ratio between an amount of
the aqueous phase and that of the oil phase, (3) a method for
adjusting the temperature of the W/O type emulsion, (4) a method
for adjusting the temperature of the outer aqueous, (5) a method
for adjusting the temperature of the W/O type emulsion with line
heater, cooler, etc. when the W/O type emulsion is injected. Each
of these methods may be employed alone or in combination with each
other.
[0132] Any of the above methods may be employed, as long as
viscosity of the W/O type emulsion is in the range of from about
150 cp to about 10,000 cp when the W/O type emulsion is changed
into the W/O/W type emulsion.
[0133] In the above method (1), the concentration of the
bio-degradable polymer in oil phase to be adjusted varies depending
on the kind of the biodegradable polymer, the kind of the organic
solvent, etc., can not be defined as restricted one, and ranges
preferably from about 10 to about 80% (W/W).
[0134] In the above method (2), ratio between an amount of the
aqueous phase and that of the oil phase to be adjusted varies
depending on the kind and amount of the drug, the character of the
oil phase, etc., can not be defined as restricted one, and ranges
preferably W/O=about 1% to about 50% (V/V).
[0135] In the above method (3), the temperature of the W/O type
emulsion to be adjusted ranges, for example, from about -20.degree.
C. to the boiling point of the organic solvent, preferably form
about 0.degree. C. to about 30.degree. C., more preferably from
about 10.degree. C. to about 20.degree. C.
[0136] Adjusting viscosity of the W/O type emulsion in the above
methods (1) and (2) can be carried out when the W/O type emulsion
is produced.
[0137] In the above method (4), before adding the W/O type emulsion
to the outer aqueous phase, the temperature of the outer aqueous
phase can be adjusted to obtain a similar result in the above
method (3). The temperature of the outer aqueous phase ranges, for
example, from about 5.degree. C. to about 30.degree. C., preferably
from about 10.degree. C. to about 25.degree. C., more preferably
from about 12.degree. C. to about 20.degree. C.
[0138] The removal of the organic solvent can be carried out by
conventional methods. For example, it is carried out by evaporating
the organic solvent by stirring with a propeller-type stirrer,
magnetic stirrer, etc. under atmospheric pressure or gradually
reducing pressure or while controlling degree of vacuum by using a
rotary evaporator, etc., etc.
[0139] When a water insoluble metal salt (or a metal salt which is
hardly soluble in water) of the physiologically active peptide is
used as a physiologically active substance, a dispersion which is
obtained by dispersing the physiologically active peptide metal
salt in the organic solvent containing the biodegradable polymer
and the fat and oil is mixed well to give an organic solvent
dispersion (hereinafter, referred to as a S/O type emulsion for the
sake of convenience) whose stability of dispersion is high and
where the physiologically active peptide metal salt is
substantially uniformly dispersed or suspended in the organic
solvent.
[0140] Examples of the above organic solvents include a similar
organic solvent to the organic solvent which is used for the
preparation of the oil phase containing the biodegradable polymer
and the fat and oil in the preparation of the above W/O type
emulsion.
[0141] For the preparation of the above S/O type emulsion,
conventional dispersion techniques can be employed. Examples of the
dispersion techniques include intermittent shaking, mixing by means
of a mixer (e.g. propeller agitator, turbine agitator, etc.),
colloid mill operation, mechanical homogenization, ultrasonication,
etc.
[0142] In this case, it is useful to use a water-soluble solvent
together with a water-insoluble solvent, if desired. As said
water-soluble solvent, any solvent can be employed as long as it is
water-soluble and can mix with the above water-insoluble solvent.
Examples of said water-soluble solvent include alcohols (e.g.
methanol, ethanol, propyl alcohol, isopropyl alcohol, etc.),
acetone, acetonitrile, etc.
[0143] In the preparation of the s/o type emulsion, the
physiologically active substance is preferably finely pulverized to
microparticles and dispersed in oil phase. The pulverized particle
size ranges usually from about 1 nm to about 30 .mu.m, preferably
about 1 nm to about 5 .mu.m, more preferably about 1 nm to about 1
.mu.m.
[0144] Subsequently, the S/O type emulsion is subjected to removal
of the organic solvent according to a similar method applied for
the above W/O type emulsion, and in-water drying is preferably
employed. Preferably, an osmotic pressure adjustor is allowed to be
contained in the outer aqueous phase in the above-mentioned
concentration. More specifically, said oil phase is added to the
second aqueous phase containing the osmotic pressure adjustor to
form an S/O/W type emulsion, followed by removing the organic
solvent in the oil phase to prepare microcapsules.
[0145] To the outer aqueous phase in the S/O/W type in-water drying
method, emulsifiers may be added. Examples of the emulsifiers
include a similar emulsifier to those described for the preparation
of the above W/O/W type emulsion.
[0146] The removal of the organic solvent in the oil phase can be
carried out by conventional methods. For example, it is carried out
by evaporating the organic solvent by stirring with a
propeller-type stirrer, magnetic stirrer, etc. under atmospheric
pressure or gradually reducing pressure or while controlling degree
of vacuum by using a rotary evaporator, etc., etc. In this case, at
the time when solidification of the polymer proceeds in some degree
and the loss caused by the release of the physiologically active
substance from the internal phase is decreased, the S/O/W type
emulsion may be warmed gradually to remove the organic solvent more
completely, which results in saving of the required time.
Alternatively, when thickening and solidification are carried out
by methods other than those based on temperature, the removal can
be carried out by merely allowing the S/O/W type emulsion to stand
with stirring, by warming it, by spraying nitrogen gas, etc.,
etc.
[0147] This removal step of the organic solvent is of importance
and greatly influences the surface structure of microcapsule
controlling the release of the physiologically active substance.
For example, rapid removal produces a number of pores on the
surface or makes pores larger in their size, which results in
increased release rate of the physiologically active substance.
[0148] The thus obtained microcapsules are collected by
centrifugation or filtration. Then, free physiologically active
substance, carriers therefor, etc. attached onto the surface of the
microcapsules are washed with distilled water repeatedly several
times, and water and the solvent in the microcapsules are removed
more completely in reduced pressure, if necessary, with
warming.
[0149] The thus obtained microcapsules are usually dispersed in
distilled water, etc., subjected to freeze-drying and stored. In
freeze drying, aggregation inhibitors may be added. Examples of
said aggregation inhibitors include water-soluble polysaccharides
(e.g. mannitol, etc.), starch (e.g. corn starch, etc.), inorganic
salts, amino acids, proteins, etc. Among others, mannitol is
preferable. Mixing ratio (by weight) between the microcapsules and
the aggregation inhibitors ranges about 50:1 to about 1:1,
preferably about 20:1 to about 1:1, more preferably about 10:1 to
about 5:1. In order to prevent the particles from aggregating with
each other while washing, aggregation inhibitors may be added to
distilled water as washing solution. Examples of said aggregation
inhibitors include water-soluble polysaccharides such as mannitol,
lactose, glucose, etc., amino acids such as glycine, etc., proteins
such as fibrin, collagen, etc., inorganic salts such as sodium
chloride, sodium hydrogen phosphate, etc., etc., preferably
mannitol.
[0150] After freeze drying, removal of water and an organic solvent
may be carried out by warming the microcapsules under reduced
pressure, if desired. When warming temperature is less than glass
transition temperature of the biodegradable polymer used as a base,
improvement of initial release of an excess amount of the
physiologically active peptide is not expected. When warming
temperature is too high, there increases a danger of melting the
microcapsules and attaching to each other, deformation of the
microcapsules, decomposition of the physiologically active
substance, decrease of activity of the physiologically active
substance, etc. In general, warming temperature is selected
appropriately, considering properties of the biodegradable polymer
used as a base (e.g. molecular weight, stability, etc.), kind of
the physiologically active peptide, average particle size of the
microcapsules, warming time, degree of dryness of the
microcapsules, warming method, etc. Preferably, the microcapsules
are warmed and dried at an appropriate temperature which is not
less than glass transition temperature of the biodegradable polymer
used as a base and where particles of the microcapsules do not
attached to each other. In particular, the microcapsules are warmed
and dried at temperatures ranging from glass transition temperature
to about 30.degree. C. higher than glass transition temperature of
the biodegradable polymer used as a base. In this specification,
glass transition temperature is defined by median glass transition
temperature which is determined using differential scanning
calorimeter at temperature increments of 10 or 20.degree. C. per
minute.
[0151] Warming and drying time varies depending on warming
temperature, an amount of the microcapsules to be treated, etc. In
general, about 24 to about 120 hours after temperature of
microcapsules themselves reach to the desired temperature are
preferable. In particular, about 48 to about 120 hours are
preferable.
[0152] A method for warming the microcapsules is not limited to a
specific method, and any method can be employed as long as the
microcapsule are uniformly warmed.
[0153] The microcapsules thus obtained are screened, and if
necessary, after light pulverization, too large microcapsules are
removed by sieving. Particle size of the microcapsules varies with
the desired degree of sustained release. When the microcapsules are
used as suspension, particle size of the microcapsules are selected
from the range satisfying the dispersibility and needle-pass
requirements. For example, the average diameter ranges preferably
from about 0.5 to 400 .mu.m, more preferably about 2 to 200
.mu.m.
[0154] In order to prepare a sterile preparation of the
microcapsules, a method for sterilizing all production steps, a
method for sterilizing with .gamma.-rays, a method for adding a
preservative, etc. are employed, and there is no limitation to a
specific method.
[0155] The microcapsules prepared according to the process of the
present invention can be readily administered orally or non-orally,
for example, as injections or implants intramuscularly,
subcutaneously, into blood vessels, organs, cava articulare, foci,
etc. Further, they can be administered in the form of various
preparations. They can also be used as raw materials in the
production of various preparations.
[0156] Examples of the above preparation include injections, oral
preparations (e.g. powders, granules, capsules, tablets), nasal
preparations, suppositories (e.g. rectal suppositories, vaginal
suppositories), etc.
[0157] These preparations can be produced according to conventional
methods. For example, when the microcapsules according to the
present invention are to be processed into injections, the
microcapsules of the present invention are dispersed in a aqueous
vehicle together with a dispersing agent (e.g. Tween 80, HCO 60
(Nikko Chemicals), carboxymethylcellulose, sodium arginate, etc.),
a preservative (e.g. methylparaben, propylparaben, benzylalcohol,
chlorobutanol, etc.), a tonicity agent (e.g. sodium chloride,
glycerin, sorbitol, glucose, etc.), etc., or an oily vehicle such
as vegetable oils (e.g. olive oil, sesame oil, peanut oil,
cotton-seed oil, corn oil, etc., propylene glycol, etc., to prepare
sustained-release injections of the microcapsules. Further,
excipients (e.g. mannitol, sorbitol, lactose, glucose, etc.) may be
added, in addition to the above components, to the above
sustained-release injections of the microcapsules in the form of
suspensions. After redispersion, the injections are solidified by
freeze drying or spray drying, and distilled water for injection or
an appropriate dispersing agent may be added just before use. In
this manner, more stable sustained-release injections can be
obtained.
[0158] When the microcapsules according to the present invention
are to be processed into, for example, tablets, they can be
prepared according to conventional preparation methods. For
example, there can be added excipients (e.g. lactose, crystalline
cellulose, sucrose, starch such as corn starch, etc., etc.),
disintegrating agents (e.g. starch such as corn starch, etc.,
croscarmellose sodium, carboxymethylstarch sodium, calcium
carmonate, etc.), binders (e.g. crystalline cellulose, gum arabic,
dextrin, carboxymethylcellulose, polyvinylpyrrolidone,
hydroxypropylcellulose, etc.), lubricants (e.g. talc, magnesium
stearate, polyethylene glycol 6000, etc.), etc. to the
microcapsules, and the mixture is compressed for molding.
[0159] When the microcapsules according to the present invention
are to be processed into, for example, nasal preparations, they are
molded into solid, semisolid or liquid. In any case, conventional
preparation methods can be used. For example, to prepare the above
solid nasal preparations, said microcapsules either as they are or
together with excipients (e.g. glucose, mannitol, starch,
microcrystalline cellulose, etc.), thickeners (e.g. natural gums,
cellulose derivatives, polyacrylates, etc.), etc. are processed
into powdery compositions. To prepare the above liquid nasal
preparations, said microcapsules are processed into an oily or
aqueous suspension in substantially the same manner as injections.
The semisolid nasal preparations may be oily or aqueous gels or
ointments. In any case, there may be added a pH adjustor (e.g.
carbonic acid, phosphoric acid, citric acid, hydrochloric acid,
sodium hydroxide, etc.), a preservative (e.g. paraoxybenzoic acid
esters, chlorobutanol, benzalkoniumchloride, etc.), etc.
[0160] When the microcapsules according to the present invention
are to be processed into suppositories, they can be prepared per se
known methods in the form of oily or aqueous solid, semisolid or
liquid, with using an oily or aqueous base. Examples of the oily
base to be used for the above composition include any one which
does not dissolve the microcapsules, for example, higher fatty acid
glycerides [e.g. cacao butter, Witepsols (Dynamit-Nobel), etc.],
medium chain fatty acid triglycerides [e.g. miglyols
(Dynamit-Nobel), etc.], vegetable oils (e.g. sesame oil, soybean
oil, cottonseed oil, etc.), etc. Examples of the aqueous base
include polyethyleneglycols, propyleneglycols, etc. Examples of the
aqueous gels include natural gums, cellulose derivatives, vinyl
polymers, polyacrylates, etc.
[0161] The microcapsules obtained according to the production
method of the present invention suppress initial burst and release
a constant amount of the drug for a long time. Therefore, the
microcapsules obtained according to the production method of the
present invention exhibits a constant efficacy with low toxicity,
thus being expected as a safe and highly effective
sustained-release preparation. In addition, when the microcapsules
are applied for the treatment of chronic disease, physical burden
can be lightened and compliance can be improved in a patient who
has to receive frequent administrations.
[0162] For example, in case of pituitary dwarfism, administration
of growth hormone is inevitable and so far growth hormone is
subcutaneously or intramuscularly administered to infants or
juvenile patients every day or every second day for several months
to 10 years or more. Since the sustained-release microcapsule
obtained by the production method of the present invention provide
these patients with sufficient treatment effect with one
administration within several weeks to months, it can contribute to
improvement of compliance in these patients.
[0163] For example, when the sustained-release microcapsule of the
present invention containing a water-soluble physiologically active
substance which is an antithrombus agent is used for the treatment
of thrombosis, the sustained-release microcapsule of the present
invention can stably maintain blood level of the drug within an
effective dose which does not cause any side effect for a long
time, while there is fear that a conventional method for
administering an antithrombus agent causes bleeding as side effect
of antithrombus activity. Therefore, the sustained-release
microcapsule of the present invention can be positively used not
only for the treatment of said chronic disease for a long time but
also for the prevention of the same. Thus, the microcapsule of the
present invention shows less side effect and low toxicity, and
therefore, can be safely administered to warm blooded mammal such
as mouse, rat, dog, horse, bovine, human, etc.
[0164] While the dosage of the sustained-release microcapsule
varies with the types and content of the physiologically active
substance as the principal ingredient, dosage forms, duration of
the release of the drug, subject animals, purposes of
administration, etc., it is sufficient if only the principal
ingredient is contained in an effective amount.
[0165] For example, when the sustained-release microcapsule of the
physiologically active peptide or a salt thereof is 1-week type
sustained-release preparation, the unit dosage for an adult is
selected from the range preferably from about 0.0001 to 10 mg/kg,
more preferably about 0.0005 to 1 mg/kg.
[0166] Number of administrations can be appropriately selected from
once a week, once per two weeks, once a month, etc., depending on
the types and content of the physiologically active substance,
dosage forms, duration of the release of the drug, subject
diseases, subject animals, etc.
[0167] When the physiologically active polypeptide as active
ingredient of the sustained-release preparation is human growth
hormone and 2-week type preparation of the sustained-release
preparation is administered to a patient of pituitary dwarfism, the
unit dosage of the active ingredient is usually selected from about
0.01 to about 5 mg/kg, preferably about 0.03 to about 1 mg/kg, and
sustained-release preparation is administered once per two weeks.
When the physiologically active substance is insulin, the unit
dosage of the active ingredient to a patient of diabetes is usually
selected from about 0.001 to about 1 mg/kg, preferably about 0.01
to about 0.2 mg/kg, and sustained-release preparation is
administered once a week.
[0168] When the sustained-release microcapsule containing
2-piperazinone-1-acetic acid derivative or a salt thereof
represented by the above formula (I) which is anticoagulant is
orally administered to a patient of unstable angina, or a patient
of ischemic complication or reobstruction of coronary or restenosis
of coronary after PTCA or coronary thrombolytic therapy, the unit
dosage for an adult (body weight: 50 kg) is selected from about 1
mg to 10 g, preferably about 1 mg to 2 g as an amount of the
microcapsule (usually, about 1 to 500 mg, preferably about 10 to
200 mg as an amount of Compound (I) as the principal
ingredient).
[0169] When the sustained-release microcapsule containing
2-piperazinone-1-acetic acid derivative or a salt thereof
represented by the above formula (I) is non-orally administered to
a patient of unstable angina, or a patient of ischemic complication
or reobstruction of coronary or restenosis of coronary after PTCA
or coronary thrombolytic therapy. The unit dosage for an adult
(body weight: 50 kg) is selected from about 0.1 to 5 ml, preferably
about 0.5 to 3 ml as a volume of a suspension to be administered as
injection (usually, about 0.05 to 50 mg, preferably 1 to 20 mg as
an amount of Compound (I) as the principal ingredient).
[0170] The sustained-release microcapsule obtained by the
production method of the present invention is stored at standard
temperatures or at a cold place, preferably at a cold place. In
this specification, standard temperature or a cold place is the
same as that defined in The Pharmacopoeia of Japan. That is,
standard temperature is 15-25.degree. C., and a cold place is the
place where the temperature is 15.degree. C. or less.
EXAMPLES
[0171] The present invention is hereinafter described in more
detail by means of, but not limited to, the following Working
Examples and Test Examples.
Working Example 1
[0172] In distilled water 1 ml were dissolved
(S)-4-(4-guanidinobenzoylami-
no)acetyl-3-[3-(4-guanidinobenzoylamino)]propyl-2-oxopiperazine-1-acetic
acid (hereinafter, briefly referred to as Compound A) hydrochloride
500 mg and L-arginine 150 mg to give an inner aqueous phase. In
methylene chloride 7.5 ml were dissolved lactic acid/glycolic acid
copolymer (lactic acid/glycolic acid=50/50 (mole %), weight-average
molecular weight 8,000) 3850 mg and vitamin E 500 mg to give an oil
phase. The oil phase was added to the inner aqueous phase, and the
mixture was emulsified with small homogenizer (Polytron) to give a
W/O type emulsion. The W/O emulsion was emulsified in 0.1% PVA
solution 800 ml (an outer aqueous phase) containing 2.7% NaCl which
was cooled to 15.degree. C. with using homomixer to give a W/O/W
type emulsion. Then the W/O/W type emulsion was slowly stirred with
a conventional propeller agitator for 3 hours. After hardening of
the microcapsules with evaporation of methylene chloride, the
microcapsules were collected by centrifugation. The collected
microcapsule were washed with purified water and subjected to
freeze drying. The microcapsule 20 mg was dissolved in
acetonitrile/distilled water (2:1 mixture) 3 ml. To the mixture was
added 0.5 N KOH-ethanol solution 3 ml, and the mixture was
subjected to hydrolysis at 25.degree. C. for 20 hours, followed by
evaporation under nitrogen gas stream. The residue was neutralized
with 0.5 N HCl, and the solution was diluted with 0.01 N HCl to
give a solution of a final amino acid concentration at about 200
nmol/ml and subjected to amino acid analyzer (Hitachi L-8500A) to
determine the content of arginine. In the microcapsules, the
content of arginine was 1.6%, and the content of vitamin E in the
microcapsules determined according to a method described in Working
Example 5 shown below was 10%.
Working Example 2
[0173] In distilled water 1 ml were dissolved Compound A
hydrochloride 500 mg and L-arginine 150 mg to give an inner aqueous
phase. In methylene chloride 8 ml were dissolved lactic
acid/glycolic acid copolymer (lactic acid/glycolic acid=50/50 (mole
%), weight-average molecular weight: 8,000) 4100 mg and vitamin E
250 mg to give an oil phase. The oil phase was added to the inner
aqueous phase, and the mixture was emulsified with small
homogenizer (Polytron) to give a W/O type emulsion. The W/O
emulsion was emulsified in 0.1% PVA solution 800 ml (an outer
aqueous phase) containing 2.7% NaCl which was cooled to 15.degree.
C. with using homomixer to give a W/O/W type emulsion. Then, the
W/O/W type emulsion was slowly stirred with a conventional
propeller agitator for 3 hours. After hardening of the
microcapsules with evaporation of methylene chloride, the
microcapsules were collected by centrifugation. The collected
microcapsules were washed with purified water, to which was added
mannitol 440 mg, and subjected to freeze drying.
Working Example 3
[0174] In distilled water 2 ml were dissolved Compound A
hydrochloride 750 mg and L-arginine 150 mg to give an inner aqueous
phase. In methylene chloride 10 ml were dissolved lactic
acid/glycolic acid copolymer (lactic acid/glycolic acid=50/50 (mole
%), weight-average molecular weight: 9,000) 3600 mg and vitamin E
500 mg to give an oil phase. According to a similar method
described in Working Example 2 the W/O type emulsion was prepared,
and thereafter the W/O/W type emulsion was prepared, and finally
freeze dried microcapsules was prepared. In the prepared
microcapsules, content of arginine and vitamin E was respectively
1.5% (w/w) and 10% (w/w).
Working Example 4
[0175] In distilled water 1 ml were dissolved Compound A
hydrochloride 500 mg and L-arginine 150 mg to give an inner aqueous
phase. In methylene chloride 8 ml were dissolved lactic
acid/glycolic acid copolymer (lactic acid/glycolic acid=50/50 (mole
%), weight-average molecular weight: 9,000) 4100 mg and vitamin E
250 mg to give an oil phase. According to a similar method
described in Working Example 2 the W/O type emulsion was prepared,
and thereafter the W/O/W type emulsion was prepared, and finally
freeze dried microcapsules was prepared. In the prepared
microcapsules, content of arginine and vitamin E was respectively
1.8% (w/w) and 5.2% (w/w).
Comparative Example 1
[0176] In distilled water 0.5 ml was dissolved Compound A 200 mg to
give an inner aqueous phase. In methylene chloride 2 ml was
dissolved lactic acid/glycolic acid copolymer (lactic acid/glycolic
acid=50/50 (mole %), weight-average molecular weight 9,000) 1800 mg
to give an oil phase. According to a similar method described in
Working Example 3 the W/O type emulsion was prepared, and
thereafter the W/O/W type emulsion was prepared, and finally freeze
dried microcapsules was prepared.
[0177] In Table 1, properties of the microcapsules obtained in
Working Example 4 and Comparative Example 1 are shown.
1TABLE 1 Initial Release of 1 day Method Entrapment in vitro
Release Test Working Example 4 96% 10% Comparative Example 1 88%
68%
[0178] As shown in Table 1, entrapment ratio of the drug into the
microcapsules was increased and initial release of 1 day with in
vitro Release Test was suppressed according to the production
method of the microcapsules characterized by adding 3% arginine to
an inner aqueous phase and 5% vitamin E to an oil phase with using
Compound A hydrochloride.
Test Example 1
[0179] The microcapsules (20 mg/kg as the drug content) obtained in
the above Working Example 1 and Comparative Example 1 were
subcutaneously administered to SD rats (male, 6 weeks) and the
plasma level of the drug after administration was determined by
ELISA, respectively. The thus obtained results were shown in FIG.
1. In FIG. 1, the curve A shows the plasma level of the drug
administered by the microcapsules of Working Example 1 and the
curve B shows the plasma level of the drug administered by the
microcapsules of Comparative Example 1. The plasma level of the
drug 1 hour after administration of the microcapsules of Working
Example 1 and Comparative Example 1 were respectively 689 ng/ml and
2926 ng/ml. Therefore, it became possible that increase of the
plasma level of the drug was suppressed at an early stage after
administration, the time-course changes of the plasma level of the
drug was not remarkable and the effective plasma level of the drug
was stably maintained for about 2 weeks in the microcapsules
prepared by adding 3% arginine to an inner aqueous phase and 10%
vitamin E to an oil phase with using Compound A hydrochloride.
Reference Example 1
[0180] To a solution (710 mg/355 ml, 5 mM NH.sub.4HCO.sub.3, pH
7.8) containing recombinant human growth hormone having methionine
at its amino terminal (prepared according to the method described
in Reference Example 14 of JP-A S62(1987)-171699) [hereinafter,
briefly referred to as Met-hGH] was gradually added dropwise
Zn(OAc).sub.2 2H.sub.2O (71 mg/5 ml H.sub.2O) solution 3.5 ml
(Met-hGH:Zn=1:7 mole) while stirring. The resulting insoluble
Met-hGH/Zn complex was centrifuged at 2,500 rpm for 20 minutes, and
the supernatant was removed. The insoluble Met-hGH/Zn complex was
redispersed in distilled water 100 ml and subjected to freeze
drying.
Working Example 5
[0181] In a mixture of methylene chloride 2.0 ml and acetonitrile
0.4 ml were dissolved lactic acid/glycolic acid copolymer (lactic
acid/glycolic acid=50/50 (mole %), weight-average molecular weight:
15,000; Wako Pure Chemical) 1275 mg and vitamin E 150 mg to give an
oil phase. In the oil phase was dispersed Met-hGH/Zn complex 75 mg
obtained in Reference Example 1. The dispersion was subjected to
ultrasonication for 5 minutes and then to a small homogenizer
(Polytron) at 15,000 rpm for 1 minute to pulverize it to
microparticles. The S/O dispersion was added to
polyvinylpyrrolidone (PVA) solution 800 ml containing 10% mannitol
cooled at 15.degree. C. and emulsified with homomixer to give a
S/O/W type emulsion. The S/O/W type emulsion was slowly stirred
with a conventional propeller agitator for 3 hours. After methylene
chloride was vaporized, the resulting microcapsules were collected
by centrifugation, washed with purified water and subjected to
freeze drying.
[0182] To the obtained microcapsules 20 mg were added ethyl acetate
5 ml and 0.1 M acetic acid buffer solution (PH=4) 1 ml. The mixture
was shaken for 10 minutes and centrifuged at 2, 500 rpm for 10
minutes. Ultraviolet (UV) absorption (294 nm) of the resulting
ethyl acetate layer was measured with an spectrophotometer (Beckman
DU 7400) to determine the content of vitamin E in the
microcapsules. The content of vitamin E in the microcapsules was
10%.
Working Example 6
[0183] In a mixture of methylene chloride 2.0 ml and acetonitrile
0.4 ml were dissolved lactic acid/glycolic acid copolymer (lactic
acid/glycolic acid=50/50 (mole %), weight-average molecular weight:
15,000) 1350 mg and vitamin E 300 mg to give an oil phase. In the
oil phase was dispersed hGH/Zn complex 75 mg obtained in Reference
Example 1. The dispersion was subjected to ultrasonication for 5
minutes and then to a small homogenizer (Polytron) at 15,000 rpm
for 1 minute to pulverize it to microparticles. According to a
similar method described in Working Example 5 the S/O dispersion
was prepared, and thereafter the S/O/W type emulsion was prepared,
and finally freeze dried microcapsules was prepared. In the
prepared microcapsules, the content of vitamin E was 17% when
determined by a method described in Working Example 5.
Comparative Example 2
[0184] In a mixture of methylene chloride 2.0 ml and acetonitrile
0.4 ml was dissolved lactic acid/glycolic acid copolymer (lactic
acid/glycolic acid=50/50 (mole %), weight-average molecular weight:
15,000) 1425 mg to give an oil phase. In the oil phase was
dispersed Met-hGH/Zn complex 75 mg obtained in Reference Example 1.
The dispersion was subjected to ultra-sonication for 5 minutes and
to a small homogenizer (Polytron) at 15,000 rpm for 1 minute to
pulverize it to microparticles. According to a similar method
described in Working Example 6 the S/O dispersion was prepared, and
thereafter the S/O/W type emulsion was prepared, and finally freeze
dried microcapsules was prepared.
Test Example 2
[0185] The microcapsules (15 mg/kg as hGH content) obtained in the
above Working Example 5, Working Example 6 and Comparative Example
2 were subcutaneously administered to SD rats (male, 6 weeks) and
the serum level of hGH was determined by RIA, respectively. The
thus obtained results were shown in FIG. 2. In FIG. 2, the curve A
shows the serum level of hGH administered by the microcapsules of
Comparative Example 2 and the curves B and C show the serum level
of the drug administered by the microcapsules of Working Examples 5
and 6, respectively. The plasma level of hGH 1 hour after
administration of the microcapsules of Comparative Example 2,
Working Example 5 and Working Example 6 were respectively 813
ng/ml, 633 ng/ml and 844 ng/ml. Bioavailabilities (BA) calculated
from AUC (area under curve) of drug blood level-time until 2 weeks
after administration were respectively 42%, 56% and 57%, compared
with intravenous administration of hGH solution. Initial burst (IB)
which was calculated by the ratio of AUC until 1 day after
administration relative to AUC until 2 weeks after administration
were respectively 83%, 79% and 72%.
[0186] In the microcapsules containing 10% vitamin E in an oil
phase prepared according to Working Example 5, increase of the
plasma level (C1h) of hGH at an early stage (1 hour) after
administration was suppressed, the high serum plasma level of hGH
was maintained for 2 weeks, and increase of BA and suppress of IB
were succeeded.
[0187] In the microcapsules containing 17% vitamin E in an oil
phase prepared according to Working Example 6, no remarkable change
in C1h was observed, the high serum plasma level of hGH was
maintained for 2 weeks, and increase of BA and suppress of IB were
succeeded.
Working Example 7
[0188] In distilled water 1 ml were dissolved Compound A
dihydrochloride 500 mg and L-arginine 300 mg to give an inner
aqueous phase. In methylene chloride 7.5 ml were dissolved lactic
acid/glycolic acid copolymer (lactic acid/glycolic acid=50/50 (mole
%), weight-average molecular weight 8,000) 3950 mg and vitamin E
250 mg to give an oil phase. The oil phase was added to the inner
aqueous phase, and the mixture was emulsified with small
homogenizer (Polytron) to give a W/O type emulsion. The W/O
emulsion was emulsified in 0.1% PVA solution 800 ml (an outer
aqueous phase) containing 2.7% NaCl which was cooled to 15.degree.
C. with using homomixer to give a W/O/W type emulsion. Then, the
W/O/W type emulsion was slowly stirred with a conventional
propeller agitator for 3 hours. After hardening of the
microcapsules with evaporation of methylene chloride, the
microcapsules were collected by centrifugation. The collected
microcapsule were washed with purified water and subjected to
freeze drying. In the microcapsule, entrapment ratio of the drug
was 90%.
Working Example 8
[0189] In distilled water 1 ml were dissolved Compound A
dihydrochloride 500 mg and L-arginine 300 mg to give an inner
aqueous phase. In methylene chloride 15 ml were dissolved lactic
acid/glycolic acid copolymer (lactic acid/glycolic acid=50/50 (mole
%), weight-average molecular weight 10,000) 3160 mg, lactic
acid/glycolic acid copolymer (lactic acid/glycolic acid=50/50 (mole
%), weight-average molecular weight 7,000) 790 mg and vitamin E 250
mg to give an oil phase. The oil phase was added to the inner
aqueous phase, and the mixture was emulsified with small
homogenizer (Polytron) to give a W/O type emulsion. The W/O
emulsion was emulsified in 0.1% PVA solution 800 ml (an outer
aqueous phase) containing 2.7% NaCl which was cooled to 15.degree.
C. with using homomixer to give a W/O/W type emulsion. Then, the
W/O/W type emulsion was slowly stirred with a conventional
propeller agitator for 3 hours. After hardening of the
microcapsules with evaporation of methylene chloride, the
microcapsules were collected by centrifugation. In the
microcapsule, entrapment ratio of the drug was 91%.
EFFECT OF THE INVENTION
[0190] According to the present invention, the microcapsules which
contains high amount of a physiologically active substance and
stable release of the drug with less initial release can be
prepared by adding a fat and oil which is dissolved in an organic
solvent containing biodegradable polymer without causing phase
separation. By using said microcapsules, side effect of the
physiologically active substance can be decreased, the
physiologically active substance can be administered for a long
time, and compliance of patients can be improved due to decrease of
the number of administrations.
* * * * *